Raynaud's phenomenon and digital necrosis in a patient treated with α interferon;Syndrome de Raynaud complique de gangrene digitale au cours d'un traitement par l'interferon alpha

Revue de Medecine Interne

Volumn 18, Issue 4, 1997, Pages 316-319

  Liozon, E ^a   Delaire, L ^a   Lacroix, P ^a   Labrousse, F ^a   Ly, K ^a   Fauchais, A L ^a   Loustaud Ratti, V ^a   Vidal, J ^a   Liozon, F ^a   Vidal, E ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

digital necrosis; hypereosinophilic syndrome; Raynaud's syndrome; thrombosis; interferon

Indexed keywords

HYDROXYUREA; ILOPROST; RECOMBINANT ALPHA2A INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT;

ADULT; AMPUTATION; ARTICLE; CASE REPORT; HUMAN; HYPEREOSINOPHILIC SYNDROME; LIMB ISCHEMIA; MALE; NECROSIS; PLETHYSMOGRAPHY; RAYNAUD PHENOMENON; SYMPTOMATOLOGY; ARTERITIS; CHEMICALLY INDUCED DISORDER; FINGER; GANGRENE; PATHOLOGY; TIME; VASCULARIZATION;

ADULT; ANTIVIRAL AGENTS; ARTERITIS; FINGERS; GANGRENE; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTERFERON ALFA-2A; MALE; RAYNAUD DISEASE; TIME FACTORS;

EID: 0030997432     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(97)84017-9     Document Type: Article

References (19)

1. Pinède L, Ninet J. Les nécroses digitales du membre supérieur. STV 1995;5:323-32
2. Cacoub P, De Lacroix I, Tazi Z, Piette JC, Godeau P. Les artériopathies iatrogènes médicamenteuses. Rev Méd Interne 1995;16:827-32
3. Guillevín L, Prin L, Blétry O. Syndrome hyperéosinophile. In: Kahn MF, Peltier AP, Meyer O, Piette JC, éds. Les maladies systémiques. Paris: Flammarion Médecine-Sciences, 1991:1052
4. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994:83:2759-79
5. Hachulla E, Hatron PY, Janin A, Robert Y, Devulder B. Artérite digitale, thrombose et syndrome hyperéosinophilique : une complication exceptionnelle. Rev Méd Interne 1995;16:434-6
6. Sangster G, Kaye SB, Calman BC, Toy JL. Cutaneous vasculitis associated with Interferon. Eur J Cancer Clin Oncol 1983;19:1647-9
7. Mansat-Krzyzanowska E, Dreno B, Chiffoleau A, Litoux P. Manifestations cardiovasculaires associées à l'interféron α 2a. Ann Méd Interne 1991;142:576-81
8. Sparano JA, Dutcher JP, Kaleya R et al. Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alfa. Cancer 1991;68:1538-44
9. Guyer DR, Tiedeman J, Yannuzzi LA et al. Interferon-associated retinopathy. Arch Ophtalmol 1993;111:350-6
10. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S. Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995;13:2401-7
11. Cortes J, Kantarjian H, O'Brien S, Robertson LE, Pierce S, Talpaz M. Results of interferon-alfa therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 1996;100:452-5
12. Creutzig A, Caspary L, Freund M. The Raynaud phenomenon and interferon therapy. Ann Intern Med 1996;125:423
13. Arslan M, Özyilkan E, Kayhan B, Telatar H. Raynaud's phenomenon associated with alfa-interferon therapy. J Intern Med 1994;235:503
14. Reid III TJ, Lombarde FA, Redmond III J, Hammond SL, Coffey JA, Ozer H. Digital vasculitis associated with interferon therapy. Am J Med 1992;92:702-3
15. Papo T, Le Thi Huong Du, Godeau P. Interferon alfa et autoimmunité. Ann Intern Med 1993;144:357-66
16. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety 1994;10:115-50
17. Roy V, Newland AC. Raynaud's phenomenon and cryoglobulinaemia associated with the use of recombinant human alfa-interferon. Lancet 1988;ii:944-5
18. Mirro J, Kalwinsky D, Whisnant J et al. Coagulopathy induced by continuous infusion of high doses of human lymphoblastoid interferon. Cancer Treat Rep 1985;69: 315-7
19. Moss J, Shore I, Woodrow D, Gresser I. Interferon-induced glomerular basement membrane and endothelial cell lesions in mice. Am J Pathol 1988;133:557-63